Twitter | Search | |
Search Refresh
Susan Rheingold May 10
Celebrating with Tom and Emily Whitehead--first pediatric patient treated with T-cell therapy--7 years cancer free today, at .
Reply Retweet Like
Paul D. Rennert May 16
going thru slides, what a great meeting, these data from Jim Kochenderfer at NCI were wild - mechanism of antigen loss relapse in MM treated with CAR-BCMA bb2121 - look at those rare BCMA-negative/dim cells that explode from wk 56 > wk 68 =>>> patient relapse
Reply Retweet Like
Paul D. Rennert May 9
Chills at the slides are wonderful
Reply Retweet Like
RDx What Else May 10
Reply Retweet Like
Penn Medicine MD May 10
The panel takes attendee questions at
Reply Retweet Like
Bruce Levine May 10
Reply Retweet Like
Stephan Grupp May 10
Always such a milestone to see this pic every year, a symbol of how far we have come. Especially meaningful to hear while participating in the first Cellicon Valley conference about the groundbreaking work that came from this amazing moment
Reply Retweet Like
@MyelomaTeacher - Cindy Chmielewski May 10
Reply Retweet Like
Denny Kraichely May 10
Replying to @BLLPHD @EWhiteheadFdn
Patients are why we do what we do! So great today to see all of the scientists attending today’s CAR T symposium give Emily Whitehead a standing ovation when she was introduced! 🔬 Amazing!!!
Reply Retweet Like
H.C. Wainwright & Co. May 16
analysts attended ’s CAR-T and the Rise of Cellicon Valley Event last week.
Reply Retweet Like
Bruce Levine May 10
Reply Retweet Like
Penn Medicine MD May 10
Translational application is huge at & . explains "We really want to get these therapies to the patients as rapidly as possible... the name of the game is to optimize pre-clinically and get trials started."
Reply Retweet Like
Biomed Postdoc Prgms Feb 15
RT : to when we tagged along to meet 's Dr. Carl June. Dr. June is Activity Director and will present in three sessions @ 'CAR-T and the Rise of Cellicon Valley' on May 9 & 10, 2019: 🔬
Reply Retweet Like
Bruce Levine May 10
Reply Retweet Like
@MyelomaTeacher - Cindy Chmielewski May 10
Throw back Friday. I remember this late breaking abstract! I left the session with a big smile on my face
Reply Retweet Like
Penn Medicine MD May 13
ICYMI: On Friday at 's event, Dr. Kochenderfer () discussed a study on the potential of bb2121 — therapy targeting B-cell maturation antigen (BCMA) — for . Read the study on : 🔬
Reply Retweet Like
@MyelomaTeacher - Cindy Chmielewski May 10
Reply Retweet Like